



EDCTP Stakeholder Meeting on HIV/AIDS

3-4 September 2013
ISCTE - Instituto Universitário de Lisboa
Av.ª das Forças Armadas, 1649-026 Lisbon, Portugal
Meeting room: Building 2, B204

Tuesday 3 September 2013

08:00-09:00	Registration
08:00-09:00	Coffee/Tea
09:00-09:30	Opening addresses <i>Professor Hannah Akuffo, Chair of the EDCTP General Assembly and member for Sweden</i> <i>Professor Charles Mgone, EDCTP Executive Director, The Netherlands</i> <i>Professor Paulo Pereira, Vice-President, FCT, Portugal</i> <i>Professor Luís Nuno Rodrigues, Pro-Rector, ISCTE-IUL, Portugal</i>
09:30-09:45	Introduction by Chairpersons <i>Professor Helen Rees, University of the Witwatersrand, South Africa</i> <i>Professor Elly Katabira, Makerere University, Uganda</i>
09:45-10:30	Plans and Progress towards EDCTP2 <i>Professor Charles Mgone, EDCTP Executive Director, The Netherlands</i>
10:15-11:00	Keynote address <i>Professor Gita Ramjee, MRC South Africa</i>
11:15-11:30	Coffee/Tea
11:30 -11:45	Treatment and Care I: Product portfolio <i>Introduction: Dr Paula Munderi, MRC / UVRU Research Unit on AIDS, Uganda</i>
11:45-13:00	<i>Discussion and recommendations</i>
13:00-14:00	Lunch
14:00-14:15	Treatment and Care II: Paediatrics, PMTCT <i>Introduction: Professor Philippe Van de Perre, University of Montpellier, France</i>
14:15 -15:15	<i>Discussion and recommendations</i>
15:15-15:30	Tea/Coffee
15:30-15:45	Treatment and Care III: Implementation research <i>Introduction: Professor Linda-Gail Bekker, Desmond Tutu HIV Centre, South Africa</i>
15:45-17:00	<i>Discussion and recommendations</i>
17:00-17:30	Summary and Closing remarks, Day 1



Wednesday 4 September 2013

08:30-09:00	Registration
08:30-09:00	Coffee/Tea
09:00-09:10	Introduction by Chairs: <i>Helen Rees, Elly Katabira</i>
09:10-09:25	Vaccines (preventive and therapeutic): Product portfolio <i>Introduction: Professor Pontiano Kaleebu, MRC/UVRI Uganda Research Unit, Uganda</i>
09:25-11:00	<i>Discussion and recommendations</i>
11:00-11:15	Coffee/tea
11:15-11:30	Prevention: Product portfolio, microbicides, PrEP <i>Introduction: Professor Sheena McCormack, MRC Clinical Trials Unit, UK</i>
11:30-13:00	<i>Discussion and recommendations</i>
13:00-13:45	Lunch
13:45-15:00	Panel discussion: partnerships and collaborations <i>Dr Alessandra Martini (EC), Dr Ricardo Pereira (FCT/representative from EDCTP General Assembly), Dr Pat Fast (IAVI), Dr Wendy Snowden (ViiV Healthcare), Mr Tom Lutalo (INDEPTH Network), Professor Peter Godfrey-Faussett (UNAIDS), Dr Jimmy Whitworth, Wellcome Trust, Ms Siobhan Malone, Bill & Melinda Gates Foundation, Dr Brigitte Jordan-Harder, German Agency for International Co-operation (GIZ)</i>
15:00-15:20	Coffee/Tea
15:20-16:00	Summary and recap of recommendations
16:00-16:15	Closing remarks

Speaker Biographies

Chairpersons



Professor Helen Rees is the founder and Executive Director of Wits RHI and Ad Hominem Professor in the Department of Obstetrics and Gynaecology. She is an Honorary Professor in the Department of Infectious and Tropical Diseases of the Clinical Research Unit at the London School of Hygiene and Tropical Medicine. Professor Rees received her Medical Degree and a Master's in Social and Political Sciences from Cambridge University and in 2002 became an alumnus of Harvard Business School. Professor Rees is one of South Africa's most well-known women scientists. Her research interests include HIV/AIDS prevention, STIs, microbicides, HIV and HPV vaccines, and broader issues relating to women's health. She is the Co-Chair of South Africa's National AIDS Council's Programme Implementing Committee and a member of the National Advisory Group on Immunisations. Previously, she served as the Chair of South Africa's Medicines Control Council and was a member of the National Research Ethics Committee. Professor Rees serves as a technical expert to many international organisations including the Global Alliance on Vaccines and Immunisation, the HIV Vaccine Advisory Committee and the HPV Vaccine expert committee of the World Health Organization, the Population Council and the US National Institutes of Health. She is currently member of the Board of the International AIDS Vaccine Initiative, IAVI.



Professor Elly Katabira is a professor of medicine at the College of Health Sciences, Makerere University. He has worked in the field of HIV as a clinician, educator and a researcher with over 100 peer-reviewed publications. Professor Katabira was the President of the International AIDS Society from 2010 to 2012 and the International Co-Chair of the International AIDS Conference in Washington DC, USA in July 2012.

Plenary Speaker



Professor Gita Ramjee is a world renowned scientist specializing in HIV prevention and treatment research with integrated care programmes among women and men in communities around the greater Durban area in South Africa. Her expertise as a world class HIV researcher and an expert in HIV prevention among women has been recognized both locally and internationally. Prof Ramjee is a Chief Specialist Scientist and the Director of the South African Medical Research Council's HIV prevention programme. As an international expert in HIV prevention trials, one of Prof Ramjee's Microbicide trial sites was chosen as the venue for a visit by Bill and Melinda Gates as well as former US president Bill Clinton. She holds an Honorary Professorship from the London School of Hygiene and Tropical Medicine.

Gita Ramjee has been involved in the clinical trials of Microbicides for over a decade. She has collaborated with all the major sponsors involved in HIV prevention research including UNAIDS, NIH, Population Council, DfID, Bill & Melinda Gates Foundation, Wellcome Trust, Novartis Pharma AG and EDCTP. Prof Ramjee has published numerous papers and is a member

of several international committees and advisory groups on HIV prevention research. She is a Fellow of the Royal Society of Medicine, a member of the Global Campaign for Microbicides Steering Committee, an invited expert in the International AIDS Vaccine Initiative, an executive committee member of the Microbicide Trials Network, the Global Prevention Working group to name a few.

Session Speakers



Dr Paula Munderi is Head of the HIV Care Research Program at the MRC/UVRI Uganda Research Unit on AIDS. She is a graduate of Makerere University Medical School and a Fellow of the Royal College of Physicians (UK). Before joining the MRC Research Unit, Dr Munderi worked at WHO Headquarters with the technical teams responsible for Guidance on HIV Care and Access to HIV Medicines. In her current role, Dr Munderi has led clinical trials on the use of antiretroviral drugs in African adults and children and has served on a number of scientific advisory committees including the WHO Technical Working Group on ART in resource-limited settings.



Professor Philippe Van de Perre is the Director of INSERM U1058 at the University of Montpellier. Previously he was the Director of the Centre Muraz in Burkina Faso and the Director of the National AIDS Reference Laboratory in Rwanda. Prof Van de Perre had lent this expertise as part of the NIH/NIAID Viral Pathogenesis Review Committee and the ANR Microbiology review panel. He is also a member of the editorial board of AIDS. Professor Van de Perre has authored 369 peer-reviewed publications.



Professor Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, is deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, UCT and chief operating officer of the Desmond Tutu HIV Foundation. She is a physician scientist with a keen interest in HIV, tuberculosis and related diseases. Prof Bekker's doctoral work focused on the host response to tuberculosis both with and in the absence of HIV co-infection. Subsequently her research interests have expanded to include programmatic and action research around antiretroviral roll out and TB integration, prevention of HIV in women, youth and men who have sex with men. Prof Bekker has contributed to a number of publications emanating from the HIV Centre on topics relevant to the South African HIV and TB epidemics. In her role

in the Foundation, she is passionate about community development and engagement and actively explores new and innovative ways to tackle the challenge that is HIV.



Professor Pontiano Kaleebu is the Director of the MRC/UVRI Uganda Research Unit on AIDS and Deputy Director Uganda Virus Research Institute, Entebbe. He is founder of the UVRI-IAVI HIV Vaccine Program and its Director 2001- 2010. The MRC/UVRI Unit is one of the two MRC-UK Units outside of the UK, a multidisciplinary Programme studying the HIV epidemic in rural and urban settings. Prof Kaleebu is Honorary Professor at the London School of Hygiene and Tropical Medicine and at Makerere University, Kampala. He holds a medical degree from Makerere University, a Diploma in Immunology and a PhD from the University of London. Prof Kaleebu leads the EDCTP East African Networks of Excellence. He has served on many committees including the WHO HIV

Vaccine Advisory Committee. His main research interest includes HIV vaccine research especially understanding protective immune responses, HIV diversity and resistance to ARVs.



Professor Sheena McCormack is based at the MRC Clinical Trials Unit and is also a Professor of Clinical Epidemiology at Imperial College, London. Professor McCormack qualified in 1982 and has been a consultant physician in HIV and sexual health since 1991, currently at 56 Dean Street. She has coordinated HIV prevention trials since 1994 initially in HIV vaccines, then expanding to microbicides and most recently oral pre-exposure prophylaxis.

Partnerships and Collaborations Panel Members



Dr Patricia Fast MD, Ph.D. trained as an immunologist and paediatrician, oversaw HIV clinical at National Institute of Allergy and Infectious Diseases Division of AIDS (1990-97), worked on vaccines against influenza and CMV at the biotech Aviron (now Medimmune/AstraZeneca). As Chief Medical Officer of the International AIDS Vaccine Initiative (IAVI) between 200-2012, she oversaw clinical trials and epidemiology within a network of African (and for several years Indian) clinical research centres. Dr Fast oversaw the development, initiation and conduct of 28 clinical trials (15 all or part in Africa), of which 25 were HIV vaccine trials, 2 trials of adherence to ARV Pre-exposure Prophylaxis, and exploring the innate immune response to Yellow Fever Vaccine. IAVI developed a network of Clinical Research Centres in Africa

that conduct world-class clinical trials, under Good Clinical, Clinical Laboratory and Participatory Practices, defined African reference ranges for hematology and serum chemistries, and compared background morbidity for 4 continents. IAVI's partners in Kenya, Rwanda, Uganda, Zambia and S Africa characterized key at-risk populations. Now Senior Technical Advisor, responsible for collaborative clinical trial and capacity-building projects, Dr Fast participates in IAVI's Central Services Facility (for the Bill & Melinda Gates Foundation). She chairs the Aeras Vaccine Advisory Committee and served on 5 Safety Review Committees. At Stanford University School of Medicine, Dr Fast advises a medical student project that yearly vaccinates thousands against influenza.



Dr Ricardo Pereira is a scientific officer with the Fundação para a Ciência e a Tecnologia (FCT), supporting a number of European projects in the area of health and life sciences research funding, including EDCTP, since February 2013. He has a PhD in International Relations (University of Coimbra, 2012), and currently is preparing a book on African States in Global Health based on his thesis on the implementation of PEPFAR in Botswana, Ethiopia and South Africa. Dr Pereira has worked in the nongovernmental humanitarian sector from 2005 and 2007 at Médecins du Monde Portugal.



Dr Alessandra Martini works as a scientific officer for HIV/AIDS research in the unit of Infectious Diseases and Public Health of DG Research and Innovation since February 2009. She graduated in Biomedical sciences at the University of Rome, and gained her PhD in molecular genetics from the medical school of the Catholic University of Leuven (Belgium) in 2004. Dr Martini entered the European Commission in 2005 to work as scientific officer in the eHealth sector. Before joining the European Commission, she also worked for BD Biosciences.



Professor Peter Godfrey-Faussett is Senior Science Adviser to UNAIDS in Geneva and Professor of International Health at the London School of Hygiene and Tropical Medicine. He is also a consultant physician at the Hospital for Tropical Diseases in London. After training in clinical infectious diseases, molecular genetics and epidemiology, he spent six years leading the Zambian AIDS-related TB (ZAMBART) project, an interdisciplinary collaborative research programme between the LSHTM, Lusaka Urban District Health Management Team and the University of Zambia, originally funded by the European Union. Thereafter he spent a year working with the Global Tuberculosis Programme of the World Health Organization, where he was responsible for developing strategies to address the combined epidemic of TB and

HIV. Following his return to London he has maintained an interest in global policies around TB and HIV and served as chairman for the Technical Review Panel of the Global Fund against AIDS, Tuberculosis and Malaria. He is the principal investigator for the ZAMSTAR study, a large community-randomised trial of interventions to reduce the prevalence of tuberculosis in communities with a high prevalence of HIV, as part of CREATE, the Consortium to Respond Effectively to the AIDS and Tuberculosis Epidemics, funded by the Bill and Melinda Gates Foundation. A regular member of WHO expert groups and review panels for NIH, Wellcome Trust and other funding bodies, his research interests remain focused on the impact that the HIV epidemic is having on TB control and on interventions to reduce the burden of both diseases.



Mr Tom Lutalo is a Principal Research Officer at Uganda Virus Research Institute (UVRI) and heads the Statistics and Data Management department at Rakai Health Sciences Program. His interests are in the demographic consequences of HIV. He has participated in all aspects of the NIH and Gates funded Rakai trials of STI control for HIV prevention, and of male circumcision for HIV/STI prevention in men and women. He is currently the Ugandan PI on the NICHD RO1 "The Problem with Male Reproductive/Sexual Health: qualitative and quantitative study, Rakai, Uganda" studying barriers to male use of HIV prevention services and male's reproductive preferences. He is also the PI on the NIH RO1 "Prevention and Planning

Linkages" looking at couple/partner dynamics and linkages in reproductive choices in the era of HIV. He is a Ugandan site leader with the Wellcome Foundation and Gates Foundation supported ALPHA (Analyzing Longitudinal Population-based HIV/AIDS data on Africa) network of 10 population-based open cohort studies measuring HIV prevalence, incidence and mortality in adults, covering 6 countries in sub-Saharan Africa. He is also the Ugandan site leader for the INDEPTH network of 41 health and demographic surveillance system (HDSS) sites in Africa,



Asia, and Oceania (20 countries); the sites offer an important and a unique opportunity to conduct observational studies to answer important public health questions and challenges affecting well characterized populations in resource-poor settings.



Dr Wendy Snowden undertook her PhD in Virology at the University of Leeds, UK, followed by a Post-doctoral position at University of California (Irvine), USA. She then entered the pharmaceutical industry where she has spent her career in infectious diseases, predominantly HIV, for the last 25 years, with the Wellcome Foundation (UK), GlaxoWellcome, Roche, GlaxoSmithKline and now ViiV Healthcare. Dr Snowden has experienced all phases of drug development, licensing and post-license activities. Her current role includes leading ViiV Healthcare International HIV Collaborative Studies programme, which supports a broad portfolio of Investigator Sponsored Trials focussing on HIV clinical research in resource-limited settings, addressing public health research priorities and with a particular interest in paediatrics, PMTCT and development and implementation of treatment strategies.